These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 22944158)

  • 1. [Effect and risk factors of pitavastatin on high sensitivity C-reactive protein in patients with hypercholesterolemia: a multilevel models analysis].
    Mao Y; Yu JM; Zhan YQ; Hu DY; Ding RJ; Zhang F; Li SC; Kong QY; Lin FL; Jia GX
    Zhonghua Yi Xue Za Zhi; 2012 Jun; 92(24):1681-5. PubMed ID: 22944158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Safety and efficacy of pitavastatin in patients with hypercholesterolemia: a multicenter study].
    Mao Y; Yu JM; Zhan YQ; Hu DY; Ding RJ; Zhang F; Li SC; Kong QY; Lin FL; Jia GX
    Zhonghua Yi Xue Za Zhi; 2012 Apr; 92(14):968-73. PubMed ID: 22781570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of pitavastatin on blood glucose and its efficacy in diabetic patients with hypercholesterolemia].
    Mao Y; Yu JM; Zhang F; Hu DY; Ding RJ; Zhan YQ; Li SC; Kong QY; Lin FL; Jia GX
    Zhonghua Nei Ke Za Zhi; 2012 Jul; 51(7):508-12. PubMed ID: 22943820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of pitavastatin on high-sensitivity C-reactive protein and adiponectin in hypercholesterolemic patients with the metabolic syndrome: the PREMIUM Study.
    Matsubara T; Naruse K; Arakawa T; Nakao M; Yokoi K; Oguri M; Marui N; Amano T; Ichimiya S; Ohashi T; Imai K; Sakai S; Sugiyama S; Ishii H; Murohara T
    J Cardiol; 2012 Nov; 60(5):389-94. PubMed ID: 22884685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia.
    Park S; Kang HJ; Rim SJ; Ha JW; Oh BH; Chung N; Cho SY
    Clin Ther; 2005 Jul; 27(7):1074-82. PubMed ID: 16154486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.
    Sansanayudh N; Wongwiwatthananukit S; Putwai P; Dhumma-Upakorn R
    Ann Pharmacother; 2010 Mar; 44(3):415-23. PubMed ID: 20179259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pitavastatin further decreases serum high-sensitive C-reactive protein levels in hypertensive patients with hypercholesterolemia treated with angiotensin II, type-1 receptor antagonists.
    Yoshika M; Komiyama Y; Masuda M; Yokoi T; Masaki H; Ohkura H; Takahashi H
    Clin Exp Hypertens; 2010; 32(6):341-6. PubMed ID: 21028996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.
    Shimabukuro M; Higa M; Tanaka H; Shimabukuro T; Yamakawa K; Masuzaki H
    Diabet Med; 2011 Jul; 28(7):856-64. PubMed ID: 21244474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). cmb@bcm.tmc.edu.
    Ballantyne CM; Davidson MH; Setze CM; Kelly MT
    J Clin Lipidol; 2011; 5(5):401-7. PubMed ID: 21981842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
    Bays HE; Davidson M; Jones MR; Abby SL
    Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial.
    Eriksson M; Budinski D; Hounslow N
    Adv Ther; 2011 Sep; 28(9):811-23. PubMed ID: 21874538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in C-reactive protein through cardiac rehabilitation and exercise training.
    Milani RV; Lavie CJ; Mehra MR
    J Am Coll Cardiol; 2004 Mar; 43(6):1056-61. PubMed ID: 15028366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
    Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
    Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study.
    Gensini GF; Gori AM; Dilaghi B; Rostagno C; Gaw A; Blanco-Colio LM; de Teresa E; Egido J; Farsang C; Leiter LA; Martineau P; Nozza A; Langer A;
    Int J Cardiol; 2010 Jul; 142(3):257-64. PubMed ID: 19217176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable effects on metabolic risk factors with daily brewer's yeast in type 2 diabetic patients with hypercholesterolemia: a semi-experimental study.
    Khosravi-Boroujeni H; Rostami A; Ravanshad S; Esmaillzadeh A
    J Diabetes; 2012 Jun; 4(2):153-8. PubMed ID: 22018047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.
    McMurray JJ; Kjekshus J; Gullestad L; Dunselman P; Hjalmarson A; Wedel H; Lindberg M; Waagstein F; Grande P; Hradec J; Kamenský G; Korewicki J; Kuusi T; Mach F; Ranjith N; Wikstrand J;
    Circulation; 2009 Dec; 120(22):2188-96. PubMed ID: 19917888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.